IMGN 632

Drug Profile

IMGN 632

Alternative Names: Anti-CD123 antibody; IMGN632

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Alkylating agents; Interleukin-3-receptor-alpha-subunit-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 09 Dec 2017 Pharmacodynamics data from a preclinical trial in Acute lymphoblastic leukaemia released by ImmunoGen
  • 03 Nov 2017 ImmunoGen plans a phase I trial for Haematological malignancies by the end of 2017
  • 16 Oct 2017 US FDA approves IND application for IMGN 632 in Haematological malignancies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top